Targets › ASPG
3 programs from 3 companies in 3 trials: 1 Phase 3, 1 Phase 4, 1 Phase 1; Oncology; next expected readout Nov 2026.
Exhibits lysophospholipase, transacylase, PAF acetylhydrolase and asparaginase activities (By similarity). Can catalyze three types of transacylation reactions: (1) acyl transfer from 1-acyl-sn-glycero-3-phosphocholine (1-acyl-GPC) to the sn-1(3) positions of glycerol and 2-acylglycerol (sn-1 to -1(3) transfer), (2) acyl transfer from 1-acyl-GPC to the sn-2 positions of 1-acyl-GPC,…. (UniProt, Q86U10)
Open in Phaseline: the race on ASPG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Wei Zhao | Pegaspargase Asparaginase depleting enzyme | ASPG | Phase 4 | Hematological Neoplasms | Dec 2026 |
| Dana-Farber Cancer Institute | Pegaspargase L-asparaginase pegylated conjugate; depletes asparagine to inhibit protein synthesis in le | ASPG | Phase 3 | Acute Lymphoblastic Leukemia, Pediatric | Nov 2026 |
| West Virginia University | Calaspargase pegol-mknl Asparaginase - depletes asparagine for leukemic blast cells | ASPG | Phase 1 | Acute Myeloid Leukemia | Feb 2030 |
Acute Lymphoblastic Leukemia, Pediatric (1) Hematological Neoplasms (1) Acute Myeloid Leukemia (1)
mixed (2), protein or peptide (1)
Dana-Farber Cancer Institute (1) Wei Zhao (1) West Virginia University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.